Founder & Non-Executive Chairman, Harmony Biosc Hold
Search every verified Jeffrey Aronin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jeffrey Aronin, founder and non-executive chairman of Harmony Biosciences, delivered a lecture in September 2020 in which he discussed his work at the intersection of life sciences and entrepreneurship. He stated that his companies focus on developing treatments for patients with diseases that have no existing therapies, and that they have obtained multiple FDA approvals. Aronin noted that only about 50 drugs are approved annually in the United States, and that many drug companies do not recoup their investment. He emphasized the importance of aligning with investors who provide long-term capital, given the unpredictable nature of scientific outcomes. Aronin also discussed the potential of artificial intelligence in healthcare, saying that AI will change the entire system in the coming years. He mentioned that his companies have developed an AI diagnosis tool for breast cancer that received FDA approval. He described gene therapy as an area where the majority of future drug approvals will occur, and noted that manufacturing remains the most challenging aspect. Aronin highlighted the underfunding of antibiotic development and the issue of patient non-compliance with medication, both of which he said contribute to higher healthcare costs.
“There are 7,000 rare diseases and only 5% have treatments. Imagine if you're one of those families with a rare disease and you don't have hope because only 50 drugs get approved every year. The big drug companies say it's not big enough for us, so we started companies focused on this area to innovate something brand ne...”
“Good ideas can all get funded, but the real important thing is to find investors—venture, private equity, family offices, big mutual funds—that are in alignment with your objectives. Science is unpredictable and you need longer-term capital because outcomes can take five to ten years.”
“Big pharmaceutical companies grow by buying other companies but struggle to innovate internally. They focus on incremental improvements in big markets, but often ignore smaller opportunities like rare diseases. Entrepreneurial companies can innovate in these underserved areas because they don't have the same infrastruc...”
“Artificial intelligence will change the entire healthcare system in the next few years. Currently, hospitals are archaic with handwritten diagnoses and inefficient processes. AI can improve diagnosis, drug discovery, and treatment, but healthcare is slow to adopt it due to regulation and complexity.”
“Developing antibiotics is a critical but neglected area because hospitals put new antibiotics on reserve, limiting sales and discouraging investment. This has led to a dangerous shortage of new antibiotics, which is a scary problem for infectious disease experts.”
“About 50% of drugs developed never make back the money spent on approval. A big factor is having enough patent runway to get the drug approved and reinvest. Patent attorneys and IP are critical but often overlooked parts of drug development.”
“A large percentage of patients don't take their medicine, which costs the healthcare system more money due to complications and ER visits. Improving patient compliance is a big issue, and while many solutions have been tried, none work perfectly.”
“In the next ten years, the majority of drugs approved will be gene therapies. While traditional biotech drugs will still be developed, gene therapies offer opportunities never before possible and can be applied in many ways, including preventative medicine.”
“The hardest part about gene therapy is manufacturing. We have an FDA-approved facility for making certain gene therapies and use it to help other companies manufacture and license products.”
“Healthcare costs are complex and large, with a quarter of government dollars going into healthcare. It's important to look at the whole system holistically, not just small pieces. New innovations that save costs and help people live longer are the solution.”
Berson Lecture Teaser: Jeff Aronin, Life Sciences Innovator.
Sign in to search the full transcript archive, filter by topic, and access every quote from Jeffrey Aronin.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →